
Profitability, historical returns, and peer comparisons.
According to Cell Source, Inc.’s latest financial reports and current stock price. The company's current ROE is 22.48%. This represents a change of 235.24% compared to the average of 6.71% of the last 4 quarters.
The mean historical ROE of Cell Source, Inc. over the last ten years is 43.82%. The current 22.48% ROE has changed -48.69% with respect to the historical average. Over the past ten years (40 quarters), CLCS's ROE was at its highest in in the March 2019 quarter at 28.54%. The ROE was at its lowest in in the December 2016 quarter at -21.74%.
Average
43.82%
Median
41.97%
Minimum
15.51%
Maximum
77.94%
Discovering the peaks and valleys of Cell Source, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 336.29%
Maximum Annual ROE = 77.94%
Minimum Annual Increase = -64.34%
Minimum Annual ROE = 15.51%
| Year | ROE | Change |
|---|---|---|
| 2025 | 20.65% | -18.65% |
| 2024 | 25.38% | -25.53% |
| 2023 | 34.08% | -16.68% |
| 2022 | 40.91% | -26.54% |
| 2021 | 55.69% | -2.94% |
| 2020 | 57.38% | -26.38% |
| 2019 | 77.94% | 81.13% |
| 2018 | 43.03% | -36.40% |
| 2017 | 67.65% | 336.29% |
| 2016 | 15.51% | -64.34% |
The current ROE of Cell Source, Inc. (CLCS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
26.70%
5-year avg
35.34%
10-year avg
43.82%
Cell Source, Inc.’s ROE is less than Celularity Inc. (142.25%), greater than IN8bio, Inc. (-91.18%), greater than CytoMed Therapeutics Limited (-91.37%), greater than Xenetic Biosciences, Inc. (-40.62%), greater than Nkarta, Inc. (-39.64%), less than MiNK Therapeutics, Inc. (83.45%), less than Tevogen Bio Holdings Inc. (248.50%), greater than Cellectis S.A. (-94.14%), greater than Precision BioSciences, Inc. (-91.60%), greater than Legend Biotech Corporation (-8.70%),
| Company | ROE | Market cap |
|---|---|---|
| 142.25% | $26.71M | |
| -91.18% | $9.65M | |
| -91.37% | $10.86M | |
| -40.62% | $5.01M | |
| -39.64% | $110.64M | |
| 83.45% | $55.53M | |
| 248.50% | $23.46M | |
| -94.14% | $104.76M | |
| -91.60% | $191.83M | |
| -8.70% | $3.97B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cell Source, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cell Source, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Cell Source, Inc.'s ROE?
How is the ROE calculated for Cell Source, Inc. (CLCS)?
What is the highest ROE for Cell Source, Inc. (CLCS)?
What is the 3-year average ROE for Cell Source, Inc. (CLCS)?
What is the 5-year average ROE for Cell Source, Inc. (CLCS)?
How does the current ROE for Cell Source, Inc. (CLCS) compare to its historical average?